Use of a2a adenosine receptor agonists

Abstract

Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A 2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.

1 .- 11 . (canceled) 
     
     
         12 . A method of producing coronary vasodilation in a human in need thereof, comprising administering to the human a bolus intravenous dose of a pharmaceutical composition comprising an aqueous buffer solution, about 0.4 mg regadenoson, and about 8-20% propylene glycol by weight of the composition, wherein the composition has a pH of about 6-8, and wherein the composition increases the average coronary peak flow velocity in the human by at least about 16.5 cm/sec. 
     
     
         13 . The method of  claim 12 , wherein the composition comprises dibasic sodium phosphate and/or monobasic sodium phosphate. 
     
     
         14 . The method of  claim 13 , wherein the dose of the composition produces a duration of action of between about 1 minute and about 12 minutes. 
     
     
         15 . A method of performing myocardial perfusion imaging of a human in need thereof, comprising administering to the human a radionuclide and a bolus intravenous dose of a pharmaceutical composition comprising an aqueous buffer solution, about 0.4 mg regadenoson, and about 8-20% propylene glycol by weight, wherein the composition has a pH of about 6-8, wherein the composition increases the average coronary peak flow velocity in the human by at least about 16.5 cm/sec, and determining areas of insufficient blood flow. 
     
     
         16 . The method of  claim 15 , wherein the dose of the composition produces a duration of action of between about 1 minute and about 12 minutes.